Protein S-glutathionylation and platelet anti-aggregating activity of disulfiram

Biochemical Pharmacology

Volumn 72, Issue 5, 2006, Pages 608-615

  Rossi, Ranieri ^a   Giustarini, Daniela ^a   Dalle Donne, Isabella ^b   Milzani, Aldo ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

ADP induced platelet aggregation; Disulfiram; Human platelets; Protein thiols; S Glutathionylated proteins

Indexed keywords

DISULFIRAM; GLUTATHIONE; GLUTATHIONE DISULFIDE; THIOL DERIVATIVE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

BLOOD PLATELETS; BLOOD PROTEINS; DISULFIRAM; GLUTATHIONE; HUMANS; OXIDATION-REDUCTION; PLATELET AGGREGATION INHIBITORS;

EID: 33746752638     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.05.021     Document Type: Article

References (61)

1. Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand 369 (1992) 15-26
2. Gessner P.K., and Gessner T. Disulfiram and its metabolite, diethyldithiocarbamate (1992), Chapman & Hall, London
3. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 20 (1999) 427-435
4. Forns X., Caballeria J., Bruguera M., Salmeron J.M., Vilella A., Mas A., et al. Disulfiram-induced hepatitis. Report of four cases and review of the literature. J Hepatol 21 (1994) 853-857
5. Brar S.S., Grigg C., Wilson K.S., Holder Jr. W.D., Dreau D., Austin C., et al. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther 3 (2004) 1049-1060
6. Cen D., Gonzalez R.I., Buckmeir J.A., Kahlon R.S., Tohidian N.B., and Meyskens Jr. F.L. Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther 1 (2002) 197-204
7. Loo T.W., and Clarke D.M. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Natl Cancer Inst 92 (2000) 898-902
8. Loo T.W., Bartlett M.C., and Clarke D.M. Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Mol Pharm 1 (2004) 426-433
9. B translocation and cell survival by the antialcoholism drug disulfiram. Int J Cancer 118 (2006) 1577-1580
10. Marikovsky M., Nevo N., Vadai E., and Harris-Cerruti C. Cu/Zn superoxide dismutase plays a role in angiogenesis. Int J Cancer 97 (2002) 34-41
11. Shiah S.G., Kao Y.R., Wu F., and Wu C.W. Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol Pharmacol 64 (2003) 1076-1084
12. Wang W., McLeod H.L., and Cassidy J. Disulfiram-mediated inhibition of NF-nB activity enhances cytotoxicity of 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 104 (2003) 504-511
13. Shen M.L., Lipsky J.J., and Naylor S. Role of disulfiram in the in vitro inhibition of rat liver mitochondrial aldehyde dehydrogenase. Biochem Pharmacol 60 (2000) 947-953
14. Shen M.L., Johnson K.L., Mays D.C., Lipsky J.J., and Naylor S. Determination of in vivo adducts of disulfiram with mitochondrial aldehyde dehydrogenase. Biochem Pharmacol 61 (2001) 537-545
15. Nobel C.S., Burgess D.H., Zhivotovsky B., Burkitt M.J., Orrenius S., and Slater A.F. Mechanism of dithiocarbamate inhibition of apoptosis: thiol oxidation by dithiocarbamate disulfides directly inhibits processing of the caspase-3 proenzyme. Chem Res Toxicol 10 (1997) 636-643
16. Nobel C.S., Kimland M., Nicholson D.W., Orrenius S., and Slater A.F. Disulfiram is a potent inhibitor of proteases of the caspase family. Chem Res Toxicol 10 (1997) 1319-1324
17. Yakisch J.S., Siden A., Eneroth P., and Cruz M. Disulfiram is a potent in vitro inhibitor of DNA topoisomerases. Biochem Biophys Res Commun 289 (2001) 586-590
18. Chu F., and O'Brian C.A. PKC sulfhydryl targeting by disulfiram produces divergent isozymic regulatory responses that accord with the cancer preventive activity of the thiuramdisulfide. Antioxid Redox Signal 7 (2005) 855-862
19. Burkitt M.J., Bishop H.S., Milne L., Tsang S.Y., Provan G.J., Nobel C.S., et al. Dithiocarbamate toxicity toward thymocytes involves their copper-catalyzed conversion to thiuram disulfides, which oxidize glutathione in a redox cycle without the release of reactive oxygen species. Arch Biochem Biophys 353 (1998) 73-84
20. Chen S.H., Liu S.H., Liang Y.C., Lin J.K., and Lin-Shiau S.Y. Oxidative stress and c-Jun-amino-terminal kinase activation involved in apoptosis of primary astrocytes induced by disulfiram-Cu(2+) complex. Eur J Pharmacol 414 (2001) 177-188
21. Nobel C.S., Kimland M., Lind B., Orrenius S., and Slater A.F. Dithiocarbamates induce apoptosis in thymocytes by raising the intracellular level of redox-active copper. J Biol Chem 270 (1995) 26202-26208
22. van Gorp R.M., van Dam-Mieras M.C., Hornstra G., and Heemskerk J.W. Effect of membrane-permeable sulfhydryl reagents and depletion of glutathione on calcium mobilisation in human platelets. Biochem Pharmacol 53 (1997) 1533-1542
23. Dalle-Donne I., Giustarini D., Colombo R., Milzani A., and Rossi R. S-Glutathionylation in human platelets by a thiol-disulphide exchange-independent mechanism. Free Radic Biol Med 38 (2005) 1501-1510
24. Essex D.W., and Li M. Redox control of platelet aggregation. Biochemistry 42 (2003) 129-136
25. Giustarini D., Dalle-Donne I., Colombo R., Petralia S., Giampaoletti S., Milzani A., et al. Protein glutathionylation in erythrocytes. Clin Chem 49 (2003) 327-330
26. Dalle-Donne I., Giustarini D., Rossi R., Colombo R., and Milzani A. Reversible S-glutathionylation of Cys(374) regulates actin filament formation by inducing structural changes in the actin molecule. Free Radic Biol Med 34 (2003) 23-32
27. Bosia A., Spangenberg P., Ghigo D., Heller R., Losche W., Pescarmona G.P., et al. Effect of GSH depletion by 1-chloro-2,4-dinitrobenzene on human platelet aggregation, arachidonic acid oxidative metabolism and cytoskeletal proteins. Thromb Res 37 (1985) 423-434
28. Heptinstall S., Groenewegen W.A., Spangenberg P., and Losche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. J Pharm Pharmacol 39 (1987) 459-465
29. Schroder H., Losche W., Strobach H., Leven W., Willuhn G., Till U., et al. Helenalin and 11alpha,13-dihydrohelenalin, two constituents from Arnica montana L., inhibit human platelet function via thiol-dependent pathways. Thromb Res 57 (1990) 839-845
30. Dalle-Donne I., Rossi R., Colombo R., Giustarini D., and Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 52 (2006) 601-623
31. Klatt P., and Lamas S. Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. Eur J Biochem 267 (2000) 4928-4944
32. Giustarini D., Rossi R., Milzani A., Colombo R., and Dalle-Donne I. S-Glutathionylation: from redox regulation of protein functions to human diseases. J Cell Mol Med 8 (2004) 201-212
33. Dalle-Donne I., Rossi R., Giustarini D., Colombo R., and Milzani A. Is there a role for S-glutathionylation of proteins in human disease?. IUBMB Life 57 (2005) 189-192
34. Delmaestro E., and Trombetta L.D. The effects of disulfiram on the hippocampus and cerebellum of the rat brain: a study on oxidative stress. Toxicol Lett 75 (1995) 235-243
35. Fuller R.K., Branchey L., Brightwell D.R., Derman R.M., Emrick C.D., Iber F.L., et al. Disulfiram treatment of alcoholism. A Veterans Administration Cooperative Study. J Am Med Assoc 256 (1996) 1449-1455
36. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties (1988), Canadian Pharmacists Association, Ottawa, Canada
37. Giustarini D., Campoccia G., Fanetti G., Rossi R., Giannerini F., Lusini L., et al. Minor thiols cysteine and cysteinylglycine regulate the competition between glutathione and protein SH groups in human platelets subjected to oxidative stress. Arch Biochem Biophys 380 (2000) 1-10
38. Bosia A., Spangenberg P., Losche W., Arese P., and Till U. The role of the GSH-disulfide status in the reversible and irreversible aggregation of human platelets. Thromb Res 30 (1983) 137-142
39. Spangenberg P., Till U., Gschmeissner S., and Crawford N. Changes in the distribution and organization of platelet actin induced by diamide and its functional consequences. Br J Haematol 67 (1987) 443-450
40. Hill T.D., White J.C., and Rao G.H.R. The influence of glutathione depleting agents on human platelet function. Thromb Res 53 (1989) 457-465
41. Essex D.W., Li M., Feinman R.D., and Miller A. Platelet surface glutathione reductase-like activity. Blood 104 (2004) 1383-1385
42. Essex D.W. The role of thiols and disulfides in platelet function. Antioxid Redox Signal 6 (2004) 736-746
43. Kim S.R., Lee J.Y., Lee M.Y., Chung S.M., Bae O.N., and Chung J.H. Association of quinone-induced platelet anti-aggregation with cytotoxicity. Toxicol Sci 62 (2001) 176-182
44. Haramaki N., Ikeda H., Takajo Y., Katoh A., Kanaya S., Shintani S., et al. Long-term smoking causes nitroglycerin resistance in platelets by depletion of intraplatelet glutathione. Arterioscler Thromb Vasc Biol 21 (2001) 1852-1856
45. Takajo Y., Ikeda H., Haramaki N., Murohara T., and Imaizumi T. Augmented oxidative stress of platelets in chronic smokers Mechanisms of impaired platelet-derived nitric oxide bioactivity and augmented platelet aggregability. J Am Coll Cardiol 38 (2001) 1320-1327
46. Bhatt D.L., and Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2 (2003) 15-28
47. Canobbio I., Balduini C., and Torti M. Signalling through the platelet glycoprotein Ib-V-IX complex. Cell Signal 16 (2004) 1329-1344
48. Abrams C.S. Intracellular signaling in platelets. Curr Opin Hematol 12 (2005) 401-405
49. Ward N.E., Stewart J.R., Ioannides C.G., and O'Brian C.A. Oxidant-induced S-glutathiolation inactivates protein kinase C-α: a potential mechanism of PKC isozyme regulation. Biochemistry 39 (2000) 10319-10329
50. Eaton P., Byers H.L., Leeds N., Ward M.A., and Shattock M.J. Detection, quantitation, purification, and identification of cardiac proteins S-thiolated during ischemia and reperfusion. J Biol Chem 277 (2002) 9806-9811
51. Ward N.E., Chu F., and O'Brian C.A. Regulation of protein kinase C isozyme activity by S-glutathiolation. Meth Enzymol 353 (2002) 89-100
52. Chu F., Chen L.H., and O'Brian C.A. Cellular protein kinase C isozyme regulation by exogenously delivered physiological disulfides-implications of oxidative protein kinase C regulation to cancer prevention. Carcinogenesis 25 (2004) 585-596
53. Pula G., Crosby D., Baker J., and Poole A.W. Functional interaction of protein kinase Cα with the tyrosine kinases Syk and Src in human platelets. J Biol Chem 280 (2005) 7194-7205
54. Jin J., and Kunapuli S.P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 95 (1998) 8070-8074
55. Ding Z., Kim S., Dorsam R.T., Jin J., and Kunapuli S.P. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101 (2003) 3908-3914
56. Kunapuli S.P., Ding Z., Dorsam R.T., Kim S., Murugappan S., and Quinton T.M. ADP receptors-targets for developing antithrombotic agents. Curr Pharm Des 9 (2003) 2303-2316
57. Sharis P.J., Cannon C.P., and Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 129 (1998) 394-405
58. 12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 31 (2005) 174-183
59. Sugidachi A., Asai F., Ogawa T., Inoue T., and Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 129 (2000) 1439-1446
60. Niitsu Y., Jakubowski J.A., Sugidachi A., and Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 31 (2005) 184-194
61. 12 antagonist, to clopidogrel in percutaneous coronary intervention; results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial. Circulation 111 (2005) 3366-3373